NEWFlashcards for any set of questions, quick-reference tables for breast, lung and prostate, and a month of access for every colleague you refer. See what changed

Lung: Metastatic squamous NSCLC - chemo-immunotherapy

Free question published 18 November 2026

RespiratoryMetastatic squamous NSCLC - chemo-immunotherapy

A 66-year-old former smoker is diagnosed with metastatic squamous-cell carcinoma of the lung. PD-L1 tumour proportion score is 5%, and squamous histology makes pemetrexed unsuitable. He has WHO performance status 1. Which first-line regimen is most appropriate?

  1. APembrolizumab plus carboplatin and pemetrexed
  2. BOsimertinib
  3. CCarboplatin and paclitaxel alone
  4. DSingle-agent pembrolizumab
  5. EPembrolizumab plus carboplatin and paclitaxel (or nab-paclitaxel)

Why E is correct

In previously untreated metastatic squamous NSCLC, adding pembrolizumab to carboplatin and paclitaxel or nab-paclitaxel improves overall survival (HR 0.64 in the primary analysis). Pemetrexed is not used in squamous histology, so the taxane-based chemo-immunotherapy backbone is the correct choice.

And why the others are not

  • APemetrexed is contraindicated in squamous histology, so a pemetrexed-containing regimen is inappropriate.
  • BOsimertinib targets EGFR mutations and has no role in driver-negative squamous NSCLC.
  • CChemotherapy alone is inferior to adding pembrolizumab in this setting.
  • DSingle-agent pembrolizumab applies to high PD-L1 expression; at TPS 5% the chemo-immunotherapy combination is preferred.

Source KEYNOTE-407 - Pembrolizumab plus carboplatin-taxane in metastatic squamous NSCLC — Novello S, Kowalski DM, Luft A, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023;41(11):1999-2006. (Primary: Paz-Ares L et al, N Engl J Med 2018;379:2040-2051).

Sitting in February? Follow the twenty-week plan.

2,500+ cited questions like this one are waiting in the vault.

See plans and pricing